Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Payables (2019 - 2025)

Korro Bio (KRRO) has disclosed Payables for 6 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables fell 61.34% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Sep 2025, down 61.34%, and an annual FY2024 reading of $4.0 million, down 45.16% over the prior year.
  • Payables was $2.3 million for Q3 2025 at Korro Bio, down from $5.2 million in the prior quarter.
  • Across five years, Payables topped out at $7.3 million in Q4 2023 and bottomed at $338000.0 in Q3 2023.
  • Average Payables over 5 years is $3.8 million, with a median of $3.9 million recorded in 2021.
  • The sharpest move saw Payables crashed 91.57% in 2023, then surged 1660.36% in 2024.
  • Year by year, Payables stood at $2.7 million in 2021, then dropped by 5.2% to $2.6 million in 2022, then surged by 179.46% to $7.3 million in 2023, then tumbled by 45.16% to $4.0 million in 2024, then tumbled by 42.38% to $2.3 million in 2025.
  • Business Quant data shows Payables for KRRO at $2.3 million in Q3 2025, $5.2 million in Q2 2025, and $4.2 million in Q1 2025.